Spots Global Cancer Trial Database for obinutuzumab
Every month we try and update this database with for obinutuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | NCT02315768 | Chronic Lymphoc... | GA101 ibrutinib | 65 Years - | University of California, San Diego | |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04408638 | Diffuse Large B... | Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | NCT04608318 | Chronic Lymphoi... | Ibrutinib Venetoclax Obinutuzumab | 18 Years - | German CLL Study Group | |
| Gazyva Infusion Reaction Investigation | NCT03529227 | Chronic Lymphoc... | 18 Years - | Healthy Future | ||
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT06428019 | Chronic Lymphoc... | Venetoclax Acalabrutinib Obinutuzumab | 18 Years - | AbbVie | |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02406742 | Leukemia, Lymph... | CC-122 Ibrutinib Obinutuzumab | 18 Years - 79 Years | Celgene | |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | NCT05861050 | Blastoid Varian... Mantle Cell Lym... Pleomorphic Var... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax | 18 Years - 80 Years | City of Hope Medical Center | |
| Lenalidomide and Obinutuzumab for Previously Untreated CLL | NCT02371590 | Chronic Lymphoc... | Lenalidomide Obinutuzumab | 18 Years - | University of California, San Diego | |
| A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | NCT03866239 | Colorectal Canc... | Obinutuzumab Atezolizumab Cibisatamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | NCT04313608 | B-cell Lymphoma | Glofitamab Gemcitabine Oxaliplatin Mosunetuzumab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03075696 | Non-Hodgkin's L... | Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | NCT04505254 | Chronic Lymphoc... Small Lymphocyt... | Acalabrutinib Obinutuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | NCT04551352 | Cutaneous Melan... Uveal Melanoma Mucosal Melanom... | RO7293583 Tocilizumab Obinutuzumab Adalimumab | 18 Years - | Hoffmann-La Roche | |
| A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | NCT02417285 | Lymphoma, Large... Lymphoma, Non-H... | Obinutuzumab CC-122 | 18 Years - | Celgene | |
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | NCT03342144 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | NCT05823701 | Diffuse Large B... | Chidamide Azacitidine obinutuzumab Liposomal mitox... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) | NCT04034056 | Follicular Lymp... | Obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years | NCT03492775 | Indolent Non-ho... | Obinutuzumab Bendamustine | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | NCT05848765 | Relapsed Follic... Refractory Foll... | Epcoritamab Lenalidomide Rituximab Obinutuzumab Bendamustine Vincristine Doxorubicin Cyclophosphamid... Prednisone Investigation a... Investigation a... | 18 Years - | University of Birmingham | |
| A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | NCT01691898 | Follicular Lymp... Diffuse Large B... | Obinutuzumab Pinatuzumab Ved... Polatuzumab Ved... Rituximab | 18 Years - | Genentech, Inc. | |
| Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT02750670 | Lymphoma, Non-H... | Obinutuzumab Gemcitabine Dexamethasone Cisplatin | 16 Years - 70 Years | University Health Network, Toronto | |
| Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma | NCT04918940 | Follicular Lymp... Mantle Cell Lym... | Determination o... | 18 Years - | Centre Henri Becquerel | |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | NCT04245722 | Lymphoma, B-Cel... Chronic Lymphoc... | FT596 Cyclophosphamid... Fludarabine Rituximab Obinutuzumab Bendamustine | 18 Years - | Fate Therapeutics | |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02992522 | B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell | Lenalidomide Obinutuzumab Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02992522 | B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell | Lenalidomide Obinutuzumab Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | NCT05197192 | Chronic Lymphoc... | Obinutuzumab Venetoclax Acalabrutinib | 18 Years - 120 Years | German CLL Study Group | |
| A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT01671904 | Chronic Lymphoc... | Bendamustine Obinutuzumab Rituximab Venetoclax | 18 Years - | Genentech, Inc. | |
| Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | NCT04703686 | Diffuse Large B... Refractory Indo... Refractory Tran... Refractory Prim... Refractory Mant... | Obinutuzumab RO7082859 | 18 Years - | The Lymphoma Academic Research Organisation | |
| A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | NCT03866239 | Colorectal Canc... | Obinutuzumab Atezolizumab Cibisatamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | NCT05783596 | Follicular Lymp... Marginal Zone L... Indolent Non-ho... | Obinutuzumab Glofitamab | 18 Years - | Dana-Farber Cancer Institute | |
| A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | NCT01905943 | Chronic Lymphoc... | Bendamustine Chlorambucil Cyclophosphamid... Fludarabine Obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT05219513 | Lymphoma, Non-H... | RO7443904 Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT02537613 | Chronic Lymphoc... | Obinutuzumab Ibrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | NCT01992653 | Lymphoma, Non H... | Cyclophosphamid... Doxorubicin Obinutuzumab Polatuzumab Ved... Prednisolone Prednisone Rituximab | 18 Years - | Genentech, Inc. | |
| Obinutuzumab in Chinese Real-world Patients With iNHL | NCT05968001 | Lymphomas Non-H... | Obinutuzumab | 18 Years - | Affiliated Hospital of Nantong University | |
| A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia | NCT02071225 | Chronic Lymphoc... | bendamustine obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | NCT04515238 | Chronic Lymphoi... | Bendamustine Obinutuzumab Zanubrutinib Venetoclax | 18 Years - | German CLL Study Group | |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | NCT02457598 | B-cell Malignan... | Tirabrutinib Idelalisib Entospletinib Obinutuzumab | 18 Years - | Gilead Sciences | |
| A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | NCT01287741 | Diffuse Large B... | Rituximab Obinutuzumab Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | Hoffmann-La Roche | |
| Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | NCT03401853 | Recurrent Diffu... Recurrent Folli... Refractory Diff... Refractory Foll... | Laboratory Biom... Pembrolizumab Rituximab Obinutuzumab | 18 Years - | University of Washington | |
| CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | NCT01998880 | Lymphocytic Leu... | obinutuzumab rituximab chlorambucil | 18 Years - | Hoffmann-La Roche | |
| A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | NCT04722601 | Follicular Lymp... | Venetoclax Obinutuzumab CC-486 | 18 Years - | University of Chicago | |
| Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | NCT01889797 | Indolent Non-Ho... | Arm A: Rituxima... Arm B: GA101 | 18 Years - | PrECOG, LLC. | |
| Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina | NCT03059251 | Chronic Lymphoc... | Obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | NCT06415708 | B Cell Lymphoma | Obinutuzumab Co... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | NCT03223610 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | Venetoclax Ibrutinib Prednisone Obinutuzumab Revlimid (lenal... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies | NCT03198650 | Part1: Advanced... Part2: r/rCLL a... Part3: Untreate... | Acalabrutinib Obinutuzumab | 20 Years - 120 Years | AstraZeneca | |
| Obinutuzumab in Marginal Zone Lymphoma | NCT03322865 | Marginal Zone L... | Obinutuzumab | 18 Years - | University of Ulm | |
| A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | NCT01287741 | Diffuse Large B... | Rituximab Obinutuzumab Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | Hoffmann-La Roche | |
| A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | NCT02391545 | CD20+ Follicula... | Duvelisib Rituximab Obinutuzumab | 18 Years - | SecuraBio | |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | NCT04883437 | Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent Non-Ho... Lymphoplasmacyt... Lymphoprolifera... Mantle Cell Lym... Marginal Zone L... | Acalabrutinib Obinutuzumab Quality-of-Life... Questionnaire A... | 18 Years - | Emory University | |
| Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | NCT03701282 | Chronic Lymphoc... Small Lymphocyt... | Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Ibrutinib Obinutuzumab Quality-of-Life... Venetoclax | 18 Years - 69 Years | National Cancer Institute (NCI) | |
| Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | NCT03737981 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Obinutuzumab Observation Venetoclax | 65 Years - | National Cancer Institute (NCI) | |
| Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | NCT02670317 | Lymphoma, B-Cel... | Obinutuzumab Ibrutinib CHOP | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | NCT04722601 | Follicular Lymp... | Venetoclax Obinutuzumab CC-486 | 18 Years - | University of Chicago | |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT06291220 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab ABBV-453 | 18 Years - | AbbVie | |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | NCT06073821 | CLL | Sonrotoclax Zanubrutinib Venetoclax Obinutuzumab | 18 Years - | BeiGene | |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | NCT03406156 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab Bendamustine Venetoclax | 18 Years - 99 Years | AbbVie | |
| Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | NCT03872180 | CCND1 Positive Mantle Cell Lym... t(11;14) Positi... | Bendamustine Obinutuzumab Venetoclax | 18 Years - | Emory University | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | NCT04895436 | Chronic Lymphoc... | Venetoclax Obinutuzumab | 18 Years - | AbbVie | |
| Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | NCT03980171 | Follicular Lymp... | Obinutuzumab Venetoclax Lenalidomide | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | NCT06043674 | Chronic Lymphoc... Richter's Trans... | Glofitamab Obinutuzumab Polatuzumab Ved... Atezolizumab Tocilizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | NCT02611908 | Chronic Lymphoc... | ibrutinib obinutuzumab | 18 Years - | University of California, San Diego | |
| A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | NCT02220842 | Lymphoma | Atezolizumab Obinutuzumab Tazemetostat | 18 Years - | Hoffmann-La Roche | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | NCT04245722 | Lymphoma, B-Cel... Chronic Lymphoc... | FT596 Cyclophosphamid... Fludarabine Rituximab Obinutuzumab Bendamustine | 18 Years - | Fate Therapeutics | |
| A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT05057494 | Chronic Lymphoc... | Acalabrutinib Venetoclax Obinutuzumab | 18 Years - 130 Years | AstraZeneca | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | NCT05536349 | Leukemia | Pirtobrutinib Obinutuzumab Venetoclax Valacyclovir Allopurinol | 18 Years - | M.D. Anderson Cancer Center | |
| Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | NCT03311126 | Mantle Cell Lym... Non-hodgkin Lym... Non Hodgkin Lym... | Bendamustine Obinutuzumab | 18 Years - | University of Wisconsin, Madison | |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | NCT05169658 | Non-Hodgkin Lym... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent B-Cell... Marginal Zone L... Recurrent Extra... Refractory Extr... | Mosunetuzumab Obinutuzumab Polatuzumab Ved... | 18 Years - | University of Washington | |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | NCT04285567 | Chronic Lymphoc... | Obinutuzumab Venetoclax Fludarabine Cyclophosphamid... Rituximab Bendamustine | 18 Years - | Hoffmann-La Roche | |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | NCT03010358 | Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom... | Entospletinib Laboratory Biom... Obinutuzumab Pharmacological... | 18 Years - | OHSU Knight Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
